61 search results for: chronic inflammation

<b>Chronic</b> Obstructive Pulmonary Disease: Disease Burden & Heterogeneity

interactivity

Chronic Obstructive Pulmonary Disease: Disease Burden & Heterogeneity

5 min

Pulmonology

Learn about the disease burden and heterogeneity of chronic obstructive pulmonary disease (COPD).

interactivity

Understanding IL-33: A Key Factor in COPD Pathogenesis

5 min

Pulmonology

Explore the role of interleukin (IL)-33 in chronic obstructive pulmonary disease (COPD) pathophysiology and its potential as a therapeutic target.

Emerging Understanding of <b>Chronic</b> Itchy Skin Diseases – Shared and Unique Drivers in AD, PN, and CSU

Infographic

Emerging Understanding of Chronic Itchy Skin Diseases – Shared and Unique Drivers in AD, PN, and CSU

5 min

Dermatology

An infographic summarizing the shared and distinct features of AD, PN, and CSU that are driven by type 2 inflammation.

What Drives <b>Chronic</b> Itch and the Itch-Scratch Cycle in Atopic Dermatitis?

videoanimation

What Drives Chronic Itch and the Itch-Scratch Cycle in Atopic Dermatitis?

6 min

Dermatology

Watch this short video to learn how type 2 inflammation, skin barrier dysfunction, and neurosensitization contribute to chronic itch and the itch-scratch cycle in atopic dermatitis

ERS 2023 | The Impact of Type 2 <b>Inflammation</b> on COPD: Examining Its Role in Disease Pathophysiology

expert video

ERS 2023 | The Impact of Type 2 Inflammation on COPD: Examining Its Role in Disease Pathophysiology

17 min

Pulmonology

Join Klaus Rabe, MD, PhD, Stephanie Christenson, MD, PhD, and Dave Singh, MD, FERS, FBPhS as they discuss the relationship between clinical presentation and disease pathology, unravel the diverse inflammatory pathways driving COPD's heterogeneity, and review the evolving clinical landscape.

Why targeting Type 2 <b>Inflammation</b> is important in the treatment of skin diseases like AD, PN and CSU

expert video

Why targeting Type 2 Inflammation is important in the treatment of skin diseases like AD, PN and CSU

5 min

Dermatology

Dr. Palomares discusses how type 2 inflammation, an aberrant immune response, underlies skin diseases like atopic dermatitis, prurigo nodularis, and chronic spontaneous urticaria, linking to their clinical symptoms.

Itch in AD, PN and CSU: Role of Type 2 <b>Inflammation</b>

expert video

Itch in AD, PN and CSU: Role of Type 2 Inflammation

27 min

Dermatology

Review the role of type 2 inflammation in the skin manifestations and itch in these chronic skin conditions.

interactivity

Worsening Disease Results in a Vicious Cycle of COPD

5 min

Pulmonology

Learn about the disease burden and heterogeneity of COPD

ADVENT On Air | Role of Type 2 <b>Inflammation</b> in COPD

Podcast

ADVENT On Air | Role of Type 2 Inflammation in COPD

21 min

Pulmonology

Drs Stephanie Christenson and Jean Bourbeau explore the role of type 2 inflammation in Chronic Obstructive Pulmonary Disease (COPD).

expert video

Role of Type 2 Cytokines in Asthma and COPD

2 min

Type 2 Inflammation

Dr Mario Castro explains how type 2 cytokines play a crucial role in airway remodeling and inflammation in asthma and COPD, impacting patient outcomes.

expert video

ERS 2023 | Heterogeneity of Inflammatory Pathways in COPD

8 min

Pulmonology

Dr. Stephanie Christenson shares an overview of inflammatory pathways underlying COPD, including type 2 inflammation.

Itch: Neuroimmune Axis in <b>Chronic</b> Pruritic Skin Diseases

expert video

Itch: Neuroimmune Axis in Chronic Pruritic Skin Diseases

11 min

Dermatology

A review of the neuroimmune axis and the mechanisms involved in perpetuating chronic itch in AD, PN, and CSU.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: AlgeriaChange country/region